JP6796058B2 - インビトロおよびインビボにおける標的の光制御除去 - Google Patents

インビトロおよびインビボにおける標的の光制御除去 Download PDF

Info

Publication number
JP6796058B2
JP6796058B2 JP2017506895A JP2017506895A JP6796058B2 JP 6796058 B2 JP6796058 B2 JP 6796058B2 JP 2017506895 A JP2017506895 A JP 2017506895A JP 2017506895 A JP2017506895 A JP 2017506895A JP 6796058 B2 JP6796058 B2 JP 6796058B2
Authority
JP
Japan
Prior art keywords
target
molecule
cells
molecular
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017506895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524002A (ja
JP2017524002A5 (enExample
Inventor
久隆 小林
久隆 小林
ピーター チョイク，
ピーター チョイク，
マーティン ジョン シュナーマン，
マーティン ジョン シュナーマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54065450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6796058(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of JP2017524002A publication Critical patent/JP2017524002A/ja
Publication of JP2017524002A5 publication Critical patent/JP2017524002A5/ja
Application granted granted Critical
Publication of JP6796058B2 publication Critical patent/JP6796058B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/44—Sample treatment involving radiation, e.g. heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/405—Concentrating samples by adsorption or absorption
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017506895A 2014-08-08 2015-08-07 インビトロおよびインビボにおける標的の光制御除去 Active JP6796058B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034990P 2014-08-08 2014-08-08
US62/034,990 2014-08-08
PCT/US2015/044168 WO2016022896A1 (en) 2014-08-08 2015-08-07 Photo-controlled removal of targets in vitro and in vivo

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020068338A Division JP7075435B2 (ja) 2014-08-08 2020-04-06 インビトロおよびインビボにおける標的の光制御除去

Publications (3)

Publication Number Publication Date
JP2017524002A JP2017524002A (ja) 2017-08-24
JP2017524002A5 JP2017524002A5 (enExample) 2018-08-02
JP6796058B2 true JP6796058B2 (ja) 2020-12-02

Family

ID=54065450

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017506895A Active JP6796058B2 (ja) 2014-08-08 2015-08-07 インビトロおよびインビボにおける標的の光制御除去
JP2020068338A Active JP7075435B2 (ja) 2014-08-08 2020-04-06 インビトロおよびインビボにおける標的の光制御除去
JP2022079474A Active JP7546013B2 (ja) 2014-08-08 2022-05-13 インビトロおよびインビボにおける標的の光制御除去
JP2024073035A Active JP7887443B2 (ja) 2014-08-08 2024-04-26 インビトロおよびインビボにおける標的の光制御除去

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020068338A Active JP7075435B2 (ja) 2014-08-08 2020-04-06 インビトロおよびインビボにおける標的の光制御除去
JP2022079474A Active JP7546013B2 (ja) 2014-08-08 2022-05-13 インビトロおよびインビボにおける標的の光制御除去
JP2024073035A Active JP7887443B2 (ja) 2014-08-08 2024-04-26 インビトロおよびインビボにおける標的の光制御除去

Country Status (9)

Country Link
US (2) US10830678B2 (enExample)
EP (1) EP3177323B2 (enExample)
JP (4) JP6796058B2 (enExample)
CN (2) CN111388672A (enExample)
AU (2) AU2015300915B2 (enExample)
CA (1) CA2954463C (enExample)
ES (1) ES2743458T5 (enExample)
SG (1) SG11201610052TA (enExample)
WO (1) WO2016022896A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022116064A (ja) * 2014-08-08 2022-08-09 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ インビトロおよびインビボにおける標的の光制御除去

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
CN121270700A (zh) 2015-08-07 2026-01-06 美国政府(由卫生和人类服务部的部长所代表) 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit)
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
WO2018013579A1 (en) * 2016-07-11 2018-01-18 cARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Sweat as a biofluid for analysis and disease identification
WO2018042018A2 (en) * 2016-09-02 2018-03-08 European Molecular Biology Laboratory Irradiation treatment of neurological sensations by photoablation
JP2020508323A (ja) * 2017-02-23 2020-03-19 ラクテン メディカル インコーポレイテッド 光免疫療法のための治療用組成物および関連する方法
CN106996892A (zh) * 2017-03-28 2017-08-01 四川出入境检验检疫局检验检疫技术中心 食品接触片材特定迁移试验采样浸泡装置
JP7216435B2 (ja) * 2018-03-09 2023-02-01 学校法人慈恵大学 血管を標的とする抗体と光増感剤とのコンジュゲート
WO2019232478A1 (en) 2018-06-01 2019-12-05 Rakuten Medical, Inc. Phthalocyanine dye conjugate compositions
JP7569309B2 (ja) * 2018-06-21 2024-10-17 株式会社島津製作所 近赤外光免疫療法による治療法を試験するための方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
JP7622946B2 (ja) * 2019-06-03 2025-01-28 眞人 光永 殺菌剤
CN114423453A (zh) * 2019-07-30 2022-04-29 乐天医药生技股份有限公司 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit)
JP2022543611A (ja) * 2019-08-07 2022-10-13 ラクテン・メディカル，インコーポレイテッド セツキシマブ－ｉｒ７００コンジュゲート組成物
CN111150844B (zh) * 2020-01-10 2022-08-19 康宏耀源（天津）科技有限公司 抗her2亲合体靶向光敏剂的合成和应用
JP2021129555A (ja) * 2020-02-18 2021-09-09 株式会社島津製作所 細胞精製装置および細胞精製方法
JP2023526033A (ja) * 2020-05-14 2023-06-20 ラクテン・メディカル，インコーポレイテッド 腫瘍を処置するための方法および組成物
CN116102741B (zh) * 2023-04-10 2023-06-20 中国农业科学院农业质量标准与检测技术研究所 脱除蜂毒致敏原用的磁性纳米复合材料及制备方法和应用
CN116592899B (zh) * 2023-04-28 2024-03-29 哈尔滨工业大学 一种基于模块化红外靶标的位姿测量系统
WO2025217516A1 (en) * 2024-04-12 2025-10-16 The Johns Hopkins University Methods and related aspects for monitoring antiretroviral drug therapy

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE547020A (enExample) 1955-04-20
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
EP0256654B1 (en) 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US5494793A (en) 1986-12-15 1996-02-27 British Technology Group Usa Inc. Monomeric phthalocyanine reagents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5196005A (en) 1991-11-26 1993-03-23 Pdt Systems, Inc. Continuous gradient cylindrical diffusion tip for optical fibers and method for making
WO1993021173A1 (en) 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US7521531B2 (en) 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US6344050B1 (en) 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
CA2397417A1 (en) 2000-01-12 2001-07-19 Sarah S. Bacus Method for quantitating a protein by image analysis
WO2001057495A2 (en) 2000-02-01 2001-08-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services Methods for predicting the biological, chemical, and physical properties of molecules from their spectral properties
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
US6706474B1 (en) 2000-06-27 2004-03-16 Board Of Trustees Of The University Of Illinois Nucleic acid enzyme biosensors for ions
AU2002348477A1 (en) 2001-05-01 2002-12-23 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030031627A1 (en) 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
US20030105299A1 (en) 2001-10-17 2003-06-05 Mallinckrodt Inc. Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
JP2003284757A (ja) 2002-01-24 2003-10-07 Seputo:Kk ヒーター付赤色光線治療器
AUPS146502A0 (en) 2002-03-28 2002-05-09 Traynor, Neil Methods and apparatus relating to improved visual recognition and safety
US6890719B2 (en) 2002-05-10 2005-05-10 The Board Of Trustess Of The University Of Illinois Fluorescence based biosensor
US7534560B2 (en) 2002-05-10 2009-05-19 The Board Of Trustees Of The University Of Illinois Simple catalytic DNA biosensors for ions based on color changes
JP4074136B2 (ja) 2002-05-29 2008-04-09 浜松ホトニクス株式会社 蛍光寿命分布画像測定装置およびその測定方法
US7597876B2 (en) 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7005518B2 (en) 2002-10-25 2006-02-28 Li-Cor, Inc. Phthalocyanine dyes
US20040120949A1 (en) 2002-11-08 2004-06-24 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7612185B2 (en) 2003-03-07 2009-11-03 The Board Of Trustees Of The University Of Illinois Nucleic acid biosensors
US20060231107A1 (en) 2003-03-07 2006-10-19 Glickman Randolph D Antibody-targeted photodynamic therapy
US20070020272A1 (en) 2003-04-30 2007-01-25 Tayyaba Hasan Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof
US7485419B2 (en) 2004-01-13 2009-02-03 The Board Of Trustees Of The University Of Illinois Biosensors based on directed assembly of particles
US20080253960A1 (en) 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
US8211883B2 (en) 2004-04-01 2012-07-03 Case Western Reserve University Topical delivery of phthalocyanines
EP1789418A1 (en) 2004-09-03 2007-05-30 Huntsman Advanced Materials (Switzerland) GmbH Compositions containing phthalocyanine dyes
US20060094026A1 (en) 2004-11-03 2006-05-04 Yi Lu Nucleic acid enzyme light-up sensor utilizing invasive DNA
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
GB0504278D0 (en) 2005-03-02 2005-04-06 Khanzada Javed Personal adornment
US7892734B2 (en) 2005-08-11 2011-02-22 The Board Of Trustees Of The University Of Illinois Aptamer based colorimetric sensor systems
EP1922077A4 (en) 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
US20080095699A1 (en) 2006-10-20 2008-04-24 Shiying Zheng Imaging contrast agents using nanoparticles
DE102005059338A1 (de) 2005-12-08 2007-06-14 Carl Zeiss Jena Gmbh Verfahren und Anordnung zur Untersuchung von Proben
WO2007070680A2 (en) 2005-12-16 2007-06-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Optically detectable probes for identification and treatment of tumors
WO2008005942A2 (en) 2006-06-30 2008-01-10 The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services. Activatable probes and methods of use
US7993927B2 (en) 2006-07-03 2011-08-09 Beth Israel Deaconess Medical Center, Inc. Histology methods
US20100065873A1 (en) 2007-03-29 2010-03-18 Koninklijke Philips Electronics N.V. Light-emitting device comprising an elastomeric layer
US8058415B2 (en) 2007-04-24 2011-11-15 The Board Of Trustees Of The University Of Illinois Aptamer- and nucleic acid enzyme-based systems for simultaneous detection of multiple analytes
GB0711560D0 (en) 2007-06-14 2007-07-25 Innova Biosciences Ltd Improvements in or relating to production of conjugates
WO2009038776A1 (en) 2007-09-18 2009-03-26 Victor Manneh Therapeutic nanoconjugates
CA2702314A1 (en) 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
EP2244741B1 (en) 2008-01-18 2015-03-25 VisEn Medical, Inc. Fluorescent imaging agents
WO2009105209A1 (en) 2008-02-19 2009-08-27 Health Research, Inc. Silica nanoparticles postloaded with photosensitizers for drug delivery in photodynamic therapy
PT2257309T (pt) 2008-02-27 2020-01-22 Yeda Res And Development Company Ltd Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos
AU2009291312A1 (en) 2008-09-15 2010-03-18 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
GB0819594D0 (en) 2008-10-24 2008-12-03 Univ Coimbrra Process
US8771741B2 (en) 2009-01-23 2014-07-08 The Penn State Research Foundation In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
US8246565B2 (en) 2009-02-25 2012-08-21 The Invention Science Fund I, Llc Device for passively removing a target component from blood or lymph of a vertebrate subject
US8317737B2 (en) 2009-02-25 2012-11-27 The Invention Science Fund I, Llc Device for actively removing a target component from blood or lymph of a vertebrate subject
GB0904825D0 (en) 2009-03-20 2009-05-06 Photobiotics Ltd Biological materials and uses thereof
EP2419478B1 (en) 2009-04-17 2018-02-28 Li-Cor, Inc. Fluorescent imaging with substituted cyanine dyes
WO2011014726A1 (en) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Mtor inhibitor and angiogenesis inhibitor combination therapy
DK2470887T3 (da) 2009-08-28 2020-04-06 Visen Medical Inc Systemer til tomografisk billeddannelse i diffuse medier ved at anvende en hybrid inversionsteknik
EP2480126B1 (en) 2009-09-22 2017-01-04 VisEn Medical, Inc. Systems and methods for virtual index-matching of diffusive media
AU2011213087B2 (en) 2010-02-02 2013-08-15 Ventana Medical Systems, Inc. Composition and method for stabilizing fluorescent particles
WO2011123742A1 (en) 2010-04-01 2011-10-06 Baylor College Of Medicine Non-radioactive agents for neuroblastoma imaging
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
WO2013009475A1 (en) 2011-07-11 2013-01-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Photosensitizing antibody-phuorophore conjugates
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2012076631A1 (en) 2010-12-07 2012-06-14 Spectracure Ab System and method for interstitial photodynamic light therapy in combination with photosensitizers
US20140076404A1 (en) 2010-12-15 2014-03-20 Mei-Chee Tan Ir-activated photoelectric systems
AU2012312041B2 (en) 2011-09-23 2017-03-16 Li-Cor, Inc. Application of reduced dyes in imaging
US9538306B2 (en) 2012-02-03 2017-01-03 Panasonic Intellectual Property Management Co., Ltd. Surround component generator
CN102585003B (zh) 2012-02-06 2017-10-31 中国科学院福建物质结构研究所 肿瘤靶向光敏免疫偶联物的制备方法及其应用
US9872904B2 (en) 2012-03-21 2018-01-23 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Photoimmunoconjugates for use in photodynamic therapy
US20160250337A9 (en) 2012-04-17 2016-09-01 Bahman Anvari Biomedical imaging and therapy using red blood cells
JP2016026471A (ja) 2012-11-27 2016-02-18 パナソニックヘルスケア株式会社 細胞識別分離方法および細胞識別分離装置
US20140220346A1 (en) 2012-12-04 2014-08-07 Memorial Sloan-Kettering Cancer Center Modular polymer hydrogel nanoparticles and methods of their manufacture
EP2958596B1 (en) 2013-02-15 2019-12-04 Case Western Reserve University Psma ligands and uses thereof
WO2014168950A1 (en) 2013-04-08 2014-10-16 University Of North Carolina At Chapel Hill Photo-responsive compounds
WO2015042325A1 (en) 2013-09-18 2015-03-26 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
WO2015057692A1 (en) 2013-10-14 2015-04-23 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
EP3148583B1 (en) 2014-06-02 2020-04-29 Li-Cor, Inc. Phthalocyanine probes and uses thereof
CA2954463C (en) 2014-08-08 2023-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
CN121270700A (zh) 2015-08-07 2026-01-06 美国政府(由卫生和人类服务部的部长所代表) 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit)
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
CN109863346A (zh) 2016-10-25 2019-06-07 乐天医药生技股份有限公司 用于光免疫治疗的光漫射装置
JP2020508323A (ja) 2017-02-23 2020-03-19 ラクテン メディカル インコーポレイテッド 光免疫療法のための治療用組成物および関連する方法
KR102103134B1 (ko) 2017-07-07 2020-04-21 라쿠텐 메디칼, 인크. 광 면역 요법에 사용하기 위한 광 확산 디바이스
WO2019199751A1 (en) 2018-04-10 2019-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022116064A (ja) * 2014-08-08 2022-08-09 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ インビトロおよびインビボにおける標的の光制御除去
JP7546013B2 (ja) 2014-08-08 2024-09-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ インビトロおよびインビボにおける標的の光制御除去

Also Published As

Publication number Publication date
CA2954463A1 (en) 2016-02-11
JP7546013B2 (ja) 2024-09-05
US11781955B2 (en) 2023-10-10
AU2015300915B2 (en) 2020-09-24
CN111388672A (zh) 2020-07-10
CN106470705B (zh) 2020-03-31
US20210010914A1 (en) 2021-01-14
EP3177323B2 (en) 2023-01-25
JP2017524002A (ja) 2017-08-24
US20170122853A1 (en) 2017-05-04
WO2016022896A1 (en) 2016-02-11
ES2743458T3 (es) 2020-02-19
ES2743458T5 (es) 2023-06-08
CA2954463C (en) 2023-11-07
EP3177323B1 (en) 2019-05-01
JP7075435B2 (ja) 2022-05-25
US10830678B2 (en) 2020-11-10
JP7887443B2 (ja) 2026-07-09
AU2015300915A1 (en) 2017-02-02
JP2020114864A (ja) 2020-07-30
AU2020294224A1 (en) 2021-01-28
AU2020294224B2 (en) 2022-10-27
SG11201610052TA (en) 2017-02-27
JP2022116064A (ja) 2022-08-09
CN106470705A (zh) 2017-03-01
EP3177323A1 (en) 2017-06-14
JP2024096263A (ja) 2024-07-12

Similar Documents

Publication Publication Date Title
JP7075435B2 (ja) インビトロおよびインビボにおける標的の光制御除去
JP7316862B2 (ja) 小細胞肺癌に対する標的療法
Li et al. Amplifying antigen-induced cellular responses with proximity labelling
Plotkin et al. Human mast cells from adipose tissue target and induce apoptosis of breast cancer cells
HUE032623T2 (hu) Anti-CXCR1 kompozíciók és módszerek
TW202102272A (zh) 光免疫療法之方法及相關之生物標記
US10928405B2 (en) Devices and methods for determining and/or isolating cells such as circulating cancer or fetal cells
Wu et al. Tumour-derived microparticles obtained through microwave irradiation induce immunogenic cell death in lung adenocarcinoma
JP2021521135A (ja) がん細胞を標的とする近赤外光線免疫療法および宿主免疫活性化の組合せ
US20180296601A1 (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
US20220040231A1 (en) Combination therapy of arms and natural killer cells
JP2022513082A (ja) 免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
JP2024536791A (ja) Ｂ７－ｈ３標的指向融合タンパク質及びそれを使用する方法
JP2017500286A (ja) 血液系腫瘍を治療するための方法
Li et al. Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors
JP2023549079A (ja) 二重標的化キメラ抗原受容体
Abdelaal et al. Removal of Malignant Cells Before Autotransplantation of Spermatogonial Stem Cells
JP2021028293A (ja) 免疫抑制性ミエロイド細胞マーカー
EP4624494A1 (en) Her2 single domain antibody and uses thereof
CN118510542A (zh) 用于处置癌的药物组合物
CN120227473A (zh) 免疫偶联药物及其药物组合物和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200406

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200518

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200616

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201113

R150 Certificate of patent or registration of utility model

Ref document number: 6796058

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250